HLS Therapeutics (TSE:HLS) Stock Price Down 1.8% – What’s Next?

HLS Therapeutics Inc. (TSE:HLS)’s stock price dropped 1.8% during trading on Monday . The company traded as low as C$3.89 and last traded at C$3.89. Approximately 32,710 shares changed hands during trading, an increase of 20% from the average daily volume of 27,313 shares. The stock had previously closed at C$3.96.

Analysts Set New Price Targets

Separately, Raymond James lifted their target price on HLS Therapeutics from C$4.00 to C$5.00 in a research report on Friday, November 22nd.

HLS Therapeutics Price Performance

The company has a market capitalization of C$123.66 million, a P/E ratio of -3.85 and a beta of 1.07. The company has a debt-to-equity ratio of 100.44, a current ratio of 2.02 and a quick ratio of 1.01. The company has a fifty day moving average price of C$3.56 and a 200 day moving average price of C$3.47.

HLS Therapeutics Company Profile

HLS Therapeutics Inc, a specialty pharmaceutical company, acquires and commercializes pharmaceutical products in the specialty central nervous system and cardiovascular markets in Canada, the United States, and internationally. The company’s product portfolio includes Clozaril, an atypical antipsychotic for management of symptoms of treatment-resistant schizophrenia; and Vascepa, an icosapent ethyl capsules for cardiovascular disease.